Invest in Canada
")/0(!2-!#%54)#!,3
")/0(!2-!
#!.!$)!.")/0(!2-!#%54)#!,33%#4/2
2%#%.4).6%34-%.43).#!.!$!
w #HARLES2IVER,ABORATORIES #ANADAPLAYSAKEYROLEINTHEGLOBALBIOPHARMACEUTICALINDUSTRYWITHPARTICULAR
)NTERNATIONALOF-ASSACHUSETTSWILL STRENGTHSINRESEARCHANDDEVELOPMENT2$ CLINICALTRIALSANDMANUFACTURING!LLOF
OPENAPRECLINICALSERVICESFACILITYIN THETOPGLOBALPHARMACEUTICALCOMPANIESINTERMSOFREVENUESHAVEOPERATIONSIN
1UEBECINWHICHISULTIMATELY #ANADASEVERALWITH2$ANDMANUFACTURINGMANDATES
EXPECTEDTOEMPLOYPEOPLE
)NGLOBALBIOPHARMACEUTICALSALESAMOUNTEDTO53BILLION4HATSAMEYEAR
w &RENCHlRM3ANOl0ASTEURINVESTED THE#ANADIANBIOPHARMACEUTICALSSECTORRECORDEDSALESOFBILLIONANDEXPORTSOF
MILLIONINANEW2$FACILITYIN NEARLYBILLION!PPROXIMATELYPERCENTOFTHESEEXPORTSWERECHANNELLEDTOTHE
/NTARIOIN 53MARKET)N#ANADAWASHOMETOPHARMACEUTICALANDBIOTECHNOLOGY
w 'LAXO3MITH+LINEINVESTEDMORETHAN ESTABLISHMENTSEMPLOYINGNEARLYPEOPLEACROSSTHECOUNTRY
MILLIONIN#ANADIAN2$IN
#ANADAOFFERSADYNAMICANDINNOVATIVEENVIRONMENTFORGLOBALBIOPHARMACEUTICAL
ALONE'3+HASOPERATIONSTHROUGHOUT
COMPANIESWITHITSlRST RATEACADEMICINSTITUTIONSWORLD CLASSINNOVATIVESCIENCE
#ANADAWITHFACILITIESIN.OVA3COTIA
RESEARCHANDCLINICALNETWORKSHIGHLYSKILLEDWORKFORCESUPPORTIVEINNOVATIONCLIMATE
1UEBEC/NTARIO!LBERTAAND"RITISH
ANDNUMEROUSPARTNERSHIPOPPORTUNITIES
#OLUMBIA
w 3ANDOZA$IVISIONOFTHE.OVARTIS
'ROUPOPENEDAMANUFACTURINGPLANTIN
1UEBECINPARTOFITSMILLION +EY#APABILITIES
INVESTMENTANNOUNCEDIN 2ESEARCHDEVELOPMENT&ROMDISCOVERYTOFULL0HASEPIVOTALTRIALSTHE#ANADIAN
w 'ERMANlRM"OEHRINGER)NGELHEIM 2$SECTORISKNOWNFORQUICKLYRECRUITINGPATIENTSADHERINGSTRICTLYTOGOODCLINICAL
COMPLETEDAMILLIONINVESTMENT PRACTICE'#0 PROTOCOLSANDGENERATINGHIGH QUALITYROBUSTDATA)NOVER
INNEWLEADING EDGELABORATORIESIN BILLIONWASSPENTONBIOPHARMACEUTICAL RELATED2$IN#ANADAWHICHBOASTSA
1UEBECIN RESEARCHCOMMUNITYOFAPPROXIMATELYINVESTIGATORSACROSSMEDICALSCHOOLS
ANDMORETHANTEACHINGHOSPITALS#ANADALEADSTHE'INGROWTHOFHEALTH
RESEARCHPATENTSANDRANKSFOURTHINTERNATIONALLYINTERMSOFITSOVERALLSHAREOFGLOBAL
-!*/2',/"!,).6%34/23 CLINICALTRIALS
).#!.!$!
-ANUFACTURING-ANYMAJORPHARMACEUTICALCOMPANIESHAVEMANUFACTURINGFACILITIESIN
!MGEN
#ANADA7ITHEASYACCESSTO53MARKETS#ANADAREPRESENTSAHIGH QUALITYCOST
!STRA:ENECA
COMPETITIVELOCATIONFOR.ORTH!MERICANMANUFACTURING#ANADAALSOPOSSESSESWORLD
"AYER
CLASSEXPERTISEINGOODMANUFACTURINGPRACTICE'-0 SMALLMOLECULEANDBIOLOGICS
"RISTOL -YERS3QUIBB
%LI,ILLY MANUFACTURINGFROMPILOTTOFULLSCALE UPAPPLICATIONSANDISHOMETOONEOFTHEWORLDS
'LAXO3MITH+LINE LARGESTGENERICDRUGMANUFACTURERS!POTEX
(OFFMAN ,A2OCHE 0HARMACEUTICALSERVICES-ANYWORLD CLASSCONTRACTSERVICECOMPANIESARELOCATED
*OHNSON*OHNSON
IN#ANADAPROVIDINGHIGH QUALITYSUPPORTIN2$CLINICALTRIALSMANUFACTURINGAND
*UBILANT/RGANOSYS
COUNTLESSOTHERSERVICESREQUIREDTOSUPPORTTHELIFESCIENCESINDUSTRY
-ERCK&ROSST
.OVARTIS
.OVOPHARM
0lZER
3ANDOZ
SANOl AVENTIS

,%!$).'#!.!$)!.#/-0!.)%3 #ANADAPLAYSAKEYROLEINTHE
!NGIOTECH0HARMACEUTICALS
!POTEX BIOPHARMACEUTICALINDUSTRY
"IO-3
"IONICHE,IFE3CIENCES WITHSALESOFBILLION
"IOVAIL
#ANGENE
#ARDIOME0HARMA#ORP
ANDEXPORTSOFNEARLY
)MMUNO6ACCINE4ECHNOLOGIES
-EDICURE)NC
BILLIONIN
4HERATECHNOLOGIES
4RANSITION4HERAPEUTICS)NC
4RILLIUM4HERAPEUTICS

5NLESSOTHERWISENOTEDALLVALUESAREIN#ANADIANDOLLARS
)-3(EALTH#ANADA 
+%9#!.!$)!.#,534%23
"RITISH#OLUMBIA
"RITISH#OLUMBIASBIOPHARMACEUTICALSSECTORCONSISTSOFOVERCOMPANIESWITHA
TOTALOFEMPLOYEESANDANNUALREVENUESOFAPPROXIMATELYMILLION4HE
+%9#
+%9 #
PROVINCESBIOPHARMACEUTICALSECTORISANCHOREDBYTWOOFTHEWORLDSlRSTPROlTABLE
BIOPHARMACEUTICALCOMPANIES1,4AND!NGIOTECH4HE"##ANCER!GENCYTHE
6ANCOUVER"#
"##ENTREFOR$ISEASE#ONTROLANDTHE5NIVERSITYOF"RITISH#OLUMBIALOCATEDIN
6ANCOUVERHOUSESOMEOFTHEPROVINCESWORLD LEADINGRESEARCHFACILITIES
#ALGARY!"
3ASKATOON3+
7INNIPEG-"
-ANITOBA 4ORONTO/.
-ONTRÏAL1#
7ITHOVERCOMPANIES2$ESTABLISHMENTSSERVICElRMSAND
#HARLOTTETOWN0%)
EMPLOYEES7INNIPEGSLIFESCIENCESCLUSTEROFFERSSIGNIlCANTCAPABILITIESIN
BIOPHARMACEUTICAL2$ANDPRODUCTIONINCLUDINGTHREEOF#ANADASTOPLIFESCIENCES
(ALIFAX.3
COMPANIESIN$IAMEDIA+ANE"IOTECHAND3AMUNE!S#ANADASTHIRD LARGEST
EXPORTEROFPHARMACEUTICALSTHEREGIONSMANUFACTURINGACTIVITYISCENTREDONlRMSSUCH
AS#ANGENE#ORPORATION!POTEX&ERMENTATION"IOVAILAND6ITA(EALTH

(OMETOTHE0UBLIC(EALTH!GENCYOF#ANADA-ANITOBAISAGLOBALCENTRE
OFEXCELLENCEININFECTIOUSDISEASEIDENTIlCATIONANDMANAGEMENTWITH
#ANADASONLY,EVELCONTAINMENTLABORATORY4HEBIOPHARMACEUTICAL
CLUSTERSAREASOFFOCUSHEREINCLUDEINFECTIOUSDISEASESCARDIOVASCULAR
ANDRESPIRATORYDISEASESONCOLOGYNEUROSCIENCENUTRACEUTICALSAND

# A NA
FUNCTIONALFOODSANDDIAGNOSTICS

!LBERTA
%DMONTONHOSTSWORLD RENOWNEDRESEARCHERSANDPUBLICLYSUPPORTED
STATE OF THE ARTFACILITIESTHATPROVIDEAWEALTHOFBIOMEDICALRESEARCH
CAPACITY%DMONTONS5NIVERSITYOF!LBERTAANDTHEUNIVERSITIESOF#ALGARY
AND,ETHBRIDGEOFFERANUNPARALLELEDENVIRONMENTFORPRIMARYRESEARCH

%$-/.4/.
3UCCESSESINCLUDETHE%DMONTON0ROTOCOLTREATMENTFOR4YPEDIABETES
ADVANCEDCANCERIMAGINGANDTREATMENTNEUROLOGICALIMAGINGANDCUTTING
EDGERESEARCHINTOTREATMENTSFORCARDIACANDINFECTIOUSDISEASES
6!.#/56%2

0RIVATE SECTORCOMPANIESADDDEPTHTOTHERESEARCHENVIRONMENTIN!LBERTA
%XAMPLESINCLUDE"IO-3-EDICAL#ORPORATIONDEVELOPINGTHERAPEUTICSTOTREAT

7)..)0%'
MULTIPLESCLEROSIS/NCOLYTICS"IOTECH)NCFOCUSINGONDEVELOPINGPRODUCTS
3!3+!4//.
TOTREATCANCERCONTRACT2$lRMS.!%*!0HARMACEUTICALSAND#HEMROUTES
#ORPORATIONAND136"IOLOGICSA'-0CONTRACTMANUFACTURINGFERMENTATION
lRM'ILEAD3CIENCESALSOOPERATESAMANUFACTURINGFACILITYIN%DMONTON
5 NI
TED 3
3ASKATCHEWAN TATES OF
!NUMBEROFOUTSTANDINGRESEARCHFACILITIESARELOCATEDIN
!ME
3ASKATCHEWANMANYINVOLVEDINCLINICALTRIALSANDCUTTING EDGEWORK
DEVELOPINGVACCINESANDlNDINGCURESFORCORONARYDISEASECANCER
DIABETESANDVIRALINFECTIONS4HEPROVINCEISHOMETOMANYINDUSTRY
LEADINGlRMSINCLUDING"IONICHE,IFE3CIENCES)NCAND0/30ILOT0LANT

3ASKATOONS.ATIONAL2ESEARCH#OUNCIL 0LANT"IOTECHNOLOGY)NSTITUTEFOCUSESON
DEVELOPINGPLANT BASEDPRODUCTSTOIMPROVETHEHEALTHANDWELLNESSOF#ANADIANS4HE
NON PROlT6ACCINEAND)NFECTIOUS$ISEASE/RGANIZATIONCREDITEDWITHlVEWORLDlRSTSIN
ANIMALVACCINERESEARCHHASEXPANDEDINTOHUMANHEALTHAPPLICATIONSINANEFFORTTOEASE
THESUFFERINGCAUSEDBYINmUENZAANDHEPATITIS#ANDADDRESSTHELACKOFEFFECTIVEVACCINES
FORNEWBORNSANDPEOPLEINDEVELOPINGCOUNTRIES


#!.!$)!.#,53
#!.!$)!. #,53 /NTARIO
4ORONTOISHOMETOONEOFTHELARGESTBIOPHARMACEUTICALCLUSTERSANDONEOFTHEBIGGESTMEDICAL
COMMUNITIESIN.ORTH!MERICA!TTHEHEARTOFTHECLUSTERISTHE$ISCOVERY$ISTRICTWHICH
ENCOMPASSESTHE-A23#ENTRETHE$ONNELLY#ENTREFOR#ELLULARAND"IOMOLECULAR2ESEARCH
RESEARCHHOSPITALSSPECIALIZEDINSTITUTIONSANDINNOVATIVELIFESCIENCESlRMS!LLHAVEHELPED
TOMAKETHE'REATER4ORONTO!REAALEADINGCENTREFORRESEARCHINGENOMICSPROTEOMICSAND
BIOINFORMATICS2ECOGNIZEDASADISTRIBUTIONHUBWITHANETWORKOFMEDICALSUPPLIERSTHEREGION
HASALSODEVELOPEDSIGNIlCANTEXPERTISEINDRUGMANUFACTURING4HE'REATER4ORONTO!REAATTRACTS
MANYWORLD LEADINGBIOPHARMACEUTICALlRMSSUCHAS"AYER%LI,ILLY'3+AND3ANOl0ASTEUR

/TTAWAISONEOFTHElRSTCITIESIN#ANADATOCAPITALIZEONTHEVASTBUSINESSPOTENTIALOF
BIOTECHNOLOGY!SATHRIVING2$CLINICALRESEARCHANDMANUFACTURINGCENTRETHECITYISHOME
TOTHE.ATIONAL2ESEARCH#OUNCILANDTOLIFESCIENCES RELATEDRESEARCHINSTITUTESTHATANNUALLY
INVESTANESTIMATEDMILLIONIN2$#OMPANIESOPERATINGIN/TTAWAINCLUDE-$3.ORDION
6ARIATION"IOTECHNOLOGIES!BBOTT0OINT OF #AREAND"EST-EDICAL#ANADA

1UEBEC
-ONTRÏALBOASTSONEOFTHELARGESTANDMOSTIMPORTANTBIOPHARMACEUTICALCLUSTERSIN
.ORTH!MERICA!SATOPLOCATIONFORBASICRESEARCHANDCONTRACTRESEARCH-ONTRÏALISALSO
VERYACTIVEINTHEDEVELOPMENTANDCOMMERCIALIZATIONOFINNOVATIVEPRODUCTSASWELLASIN
VENTURECAPITALFUNDINGFORBIOTECHNOLOGYlRMS%MPLOYINGAPPROXIMATELYPEOPLE
THECITYSCLUSTERBENElTSFROMAWEALTHOFEXPERTISEINCLINICALRESEARCHACOREOFDYNAMIC
ENTREPRENEURSINBIOINFORMATICSANDMEDICALTECHNOLOGIESANDISHOMETOMANUFACTURERS
OFPATENTEDANDGENERICPRODUCTS"OASTINGTOPLEVELEXPERTISEINVACCINERESEARCHANDIN

A DA
THEBIO MANUFACTURINGOFTHERAPEUTICPROTEINS-ONTRÏALALSOHASALEADINGREPUTATIONIN
2$HOSTINGANUMBEROFRENOWNEDINTERNATIONALRESEARCHCENTRESSUCHASTHE-C'ILL
5NIVERSITYAND'ÏNOME1UÏBEC)NNOVATION#ENTREANDTHE"IOTECHNOLOGY
2ESEARCH)NSTITUTE7ORLD CLASSlRMSSUCHAS!STRA:ENECA'3+-ERCK
&ROSST.OVARTIS0lZERSANOl AVENTISAND7YETHOPERATEIN-ONTRÏAL

4HE#ITYOF1UÏBECSHEALTHSECTORHASALARGECONCENTRATIONOF
JOBSINVACCINEPRODUCTIONCONTRACTRESEARCHDIAGNOSTICS
ANDTHEMANUFACTUREOFMEDICALEQUIPMENTANDMEDICAL
TECHNOLOGIES3INCEPHARMACEUTICALCOMPANIES
#)49/&15³"%#

HAVEINVESTEDCLOSETOBILLIONINTHEIRPRODUCTION
UNITSLOCATEDINTHEPROVINCEOF1UEBECDUEINLARGE
PARTTOTHEABUNDANTPOOLOFAVAILABLEACADEMIC
TECHNICALANDSPECIALIZEDLABOUR4HE#ITYOF1UÏBEC
-/.42³!,

REGIONISHOMETOMANYINDUSTRY LEADINGlRMSINCLUDING

‰TERNA:ENTARIS!NAPHARMAND'3+ASWELLASTOSEVEN
/44!7!

RESEARCHCENTRESTHATFOCUSONCUTTING EDGERESEARCHINCARDIOLOGY
4/2/.4/

GENOMICSINFECTIOUSDISEASESIMMUNOLOGYOBESITYONCOLOGY

NEUROSCIENCEFUNCTIONALFOODSANDNUTRACEUTICALS
(!,)&!8

RICA
.OVA3COTIA
(ALIFAXISHOMETOANUMBEROFLEADINGCOMPANIESINVOLVEDINTHE
DEVELOPMENTOFTHERAPEUTICPRODUCTSANDTHEMANUFACTURINGAND
DISTRIBUTIONOFNATURALHEALTHPRODUCTS3UCHlRMSINCLUDE-ERCK&ROSST
#ANADA+YTOGENICS0HARMACEUTICALS/CEAN.UTRITIONAND!SCENTA
(EALTHAlRMTHATHOLDSTHELARGESTSHAREOF#ANADASMARKETFOR
OMEGA SUPPLEMENTS(ALIFAXALSOBOASTS4HE"RAIN2EPAIR#ENTRE
AMULTIDISCIPLINARYCOLLABORATIONLINKINGMORETHANWORLD CLASS
RESEARCHERSANDPHYSICIANSSPECIALIZINGINGROUNDBREAKINGTREATMENTSAND
TECHNOLOGIESINTHElELDOFBRAINREPAIR
 ).6%34-%.4,/#!4)/."%.#(-!2+).'

")/0(!2
-%4(/$/,/'9
4HISBENCHMARKINGSTUDYASSESSESTHECOMPETITIVENESSOFANUMBEROF#ANADIANCLUSTERS
AGAINSTCOMPETINGINTERNATIONALBUSINESSLOCATIONS"ASEDONANINVESTORSPERSPECTIVETHE
RESEARCHANDANALYSISUSESAREPRESENTATIVEINVESTMENTPROJECTPROTOTYPEABIOTECHNOLOGY
2$FACILITYFOCUSEDONDRUGDISCOVERYANDCLINICALTRIALSASWELLASAFULLYINTEGRATED
PHARMACEUTICALOPERATIONINVOLVEDWITH2$ANDPRODUCTIONOFCOMMERCIALPRODUCTSˆSEE
PROlLEONPAGE TOASSESSCRITERIATHATCORPORATEDECISIONMAKERSTYPICALLYEXAMINEWHEN
EVALUATINGLOCATIONALTERNATIVESFORFOREIGNINVESTMENT

4HISINTERNATIONALLOCATIONBENCHMARKINGEXERCISEWASCONDUCTEDBY)"- 0LANT,OCATION
)NTERNATIONAL)"- 0,) ARENOWNEDGLOBALLOCATIONCONSULTANCY)"- 0,)PERFORMED
OBJECTIVERESEARCHTOASSESSTHECOMPARATIVECOSTANDQUALITYOFDOINGBUSINESSINVARIOUS
LOCATIONSSIMULATINGTHEAPPROACHUSEDBYINVESTORSWHENSCREENINGCANDIDATESFOR
CORPORATEINVESTMENTPROJECTS4HEBENCHMARKINGSTUDYEXAMINEDTOlNANCIALAND
QUALITATIVELOCATIONINDICATORSINTHEASSESSMENTOFEACHINDUSTRYSUBSECTOR

4OASSESSTHEQUALITYOFALOCATIONSOPERATINGBUSINESSENVIRONMENTDATAWERECOLLECTED
FROMAVARIETYOFSOURCESFORTHEDIFFERENTSUBFACTORSINEACHOFTHECATEGORIESFEATUREDINTHE
OPERATINGENVIRONMENTTABLEPAGE $ATAFORTHEQUALITATIVEASSESSMENTWERETRANSLATED
INTOCOMPARABLESCORINGSZEROTO FOREACHCATEGORYANDSUBFACTORUSINGAWEIGHTED
SCOREBOARDAPPROACH7EIGHTSWEREASSIGNEDTOEACHLOCATIONCATEGORYANDSUBFACTOR
TODEMONSTRATETHEIRRELATIVEIMPORTANCEINTHELOCATIONSELECTIONPROCESS4HESEWEIGHTS
ARESPECIlCTOEACHINDUSTRYSUBSECTORANDAREBASEDON)"- 0,)SEXPERIENCEINHELPING
INVESTORSMAKESTRATEGICDECISIONSWHENCHOOSINGLOCATIONS

!HIGH LEVELlNANCIALANALYSISWASALSOCONDUCTEDTOTAKEINTOACCOUNTMAJORLOCATION
SENSITIVEINVESTMENTANDOPERATINGCOSTSANDREVENUESFOREACHREPRESENTATIVEPROJECT
PROlLE/PERATINGCOSTANDCASHmOWPROJECTIONSHAVEBEENCALCULATEDANDDISCOUNTEDOVER
A YEARPERIODINCORPORATINGANTICIPATEDINmATIONRATESTODETERMINETHEIRNETPRESENT
VALUE

BENCHMARKINGTHECOMPARATIVE
COSTANDQUALITYOFDOING
BUSINESSINGLOBALLOCATIONS

).6%34-%.4,/#!


).6%34-%.4,/#!4)/."%.#(-!2+).'
2%02%3%.4!4)6%02/*%#402/&),% 2%02%3%.4!4)6%02/*%#402/&),%
"IOTECH2$ &ULLY)NTEGRATED0HARMACEUTICAL/PERATION

'%.%2!,$%3#2)04)/. /0%2!4).'#/34!.!,93)3 '%.%2!,$%3#2)04)/. /0%2!4).'#/34!.!,93)3

/&/0%2!4)/.3 02/*%#42%15)2%-%.43&/2 /&/0%2!4)/.3 02/*%#42%15)2%-%.43&/2
&).!.#)!,-/$%,,).' &).!.#)!,-/$%,,).'
"IOTECH2$FACILITY 2ESEARCHDEVELOPMENT
FOCUSEDONDRUG ,!"/52 02/0%249 ANDPRODUCTIONOF ,!"/52 02/0%249
DISCOVERYANDCLINICAL (%!$#/5.4 COMMERCIALHUMAN (%!$#/5.4
,ANDACRES ,ANDACRES
TRIALS PHARMACEUTICAL
"IOLOGY "UILDING 0RODUCTION "UILDING
PRODUCTS
3CIENTISTS SQFT /PERATIVES SQFT
,ABORATORY 3ENIOR
+%902/*%#4$2)6%23 3PECIALISTSAND +%902/*%#4$2)6%23 3CIENTISTS
54),)4)%3 54),)4)%3
w !VAILABILITYOFHIGHLY 4ECHNICIANS w !VAILABILITYOF ,ABORATORY
0OWER 0OWER
SKILLEDPERSONNEL #LINICAL SKILLEDLABOUR 4ECHNICIANS
LABORATORY -ONTHLY SCIENTISTS -ONTHLY
2ESEARCHERS %NGINEERS
SPECIALISTS #ONSUMPTION TECHNICIANS #ONSUMPTION
/PERATIONS K7H -ANAGEMENTAND K7H
RESEARCHERSETC -ANAGERS PRODUCTION
7ATER !DMINISTRATION 'AS
w !CCESSTO OPERATIVES
'ENERAL/FlCE $AILY
RESEARCHAND w !TTRACTIVENESSFOR -ONTHLY
#LERKS #ONSUMPTION -!#().%29!.$
TECHNOLOGY INTERNATIONAL #ONSUMPTION
GAL %15)0-%.4 -CF
UNIVERSITIES RECRUITS
INCUBATORS2$ # 7ATER
w !CCESSTO
FUNDINGETC $AILY
RESEARCHAND
3!,%3 #ONSUMPTION
TECHNOLOGY
GAL
UNIVERSITIES #
#!0)4!,).6%34-%.4
INCUBATORS2$
#MILLION FUNDINGETC

/0%2!4).'%.6)2/.-%.4 /0%2!4).'%.6)2/.-%.4

'%.%2!,"53).%33%.6)2/.-%.4w
'%.%2!,"53).%33%.6)2/.-%.4w

w!VAILABILITYOFlNANCIALSUPPORTINCENTIVESw1UALITYOFSUPPORTFROMLOCAL w1UALITYOFSUPPORTFROMLOCALGOVERNMENTDEVELOPMENTAGENCIES
GOVERNMENTDEVELOPMENTAGENCIESw#OMPLIANCEWITHPROTECTIONOF w!VAILABILITYOFlNANCIALSUPPORTINCENTIVESw"USINESSPERMITTING
PRIVACYREGULATIONSINFORMATIONSECURITY)0RIGHTSw0OLITICALSTABILITY PROCEDURESw#OMPLIANCEWITHPROTECTIONOFPRIVACYREGULATIONSINFORMATION
w%CONOMICANDlNANCIALSTABILITY SECURITY)0RIGHTSw0OLITICALSTABILITYw%CONOMICANDlNANCIALSTABILITY

,/#!,0/4%.4)!,4/2%#25)43+),,%$34!&&w
,/#!,0/4%.4)!,4/2%#25)43+),,%$34!&&w

w0RESENCEOFEXPERIENCEDEMPLOYEESPHARMACEUTICALANDBIOTECHRELATED  w0RESENCEOFEXPERIENCEDPHARMACEUTICALEMPLOYEES2$AND
w0RESENCEOFSTUDENTPOPULATIONw/VERALLSIZEOFLABOURPOOL MANUFACTURING w/VERALLSIZEOFLABOURPOOLw/VERALLTIGHTNESSINTHE
w/VERALLTIGHTNESSINTHELABOURMARKETUNEMPLOYMENT LABOURMARKETUNEMPLOYMENT w0RESENCEOFSTUDENTPOPULATION

02%3%.#%/&).$53429#,534%2w
02%3%.#%/&).$53429#,534%2w

w)MPORTANCEOF2$w0ROXIMITYTOlNANCEREGULATORS w0RESENCEOFINDUSTRYBASEw-ARKETPROXIMITYw)MPORTANCEOF2$
w0RESENCEOFINDUSTRYBASE
w-ARKETPROXIMITYACCESSTOCUSTOMERSSUPPLIERS
&,%8)"),)49/&,!"/522%'5,!4)/.3w

w7ORKINGTIMEREGULATIONSw(IRINGlRINGmEXIBILITY
&,%8)"),)49/&,!"/522%'5,!4)/.3w
w)NDUSTRIALRELATIONSATTITUDEOFUNIONS
w(IRINGlRINGmEXIBILITYw7ORKPERMITSw7ORKINGTIMEREGULATIONS
w)NDUSTRIALRELATIONSATTITUDEOFUNIONS
).&2!3425#452%#/--5.)#!4)/.3w

w(IGHWAYNETWORKCONGESTIONw!IRACCESSw2ELIABILITYOFPOWER
).&2!3425#452%#/--5.)#!4)/.3w
SUPPLYw1UALITYRELIABILITYOF)4TELECOMMUNICATIONSw0UBLICTRANSPORT
w!IRACCESSw1UALITYRELIABILITYOF)4TELECOMMUNICATIONSw0UBLIC
TRANSPORTw(IGHWAYNETWORKCONGESTIONw2ELIABILITYOFPOWERSUPPLY
2%!,%34!4%w

w!VAILABILITYOFLARGEINDUSTRIALSITES
,)6).'%.6)2/.-%.4w

w!TTRACTIVENESSFORYOUNGINTERNATIONALRECRUITS ,)6).'%.6)2/.-%.4w

w!TTRACTIVENESSFOREXPATRIATES w!TTRACTIVENESSFORYOUNGINTERNATIONALRECRUITS
w!TTRACTIVENESSFOREXPATRIATESw#OSTOFLIVING


&ACTORCATEGORYWEIGHTCORRESPONDINGLOCATIONFACTORSARERANKEDINORDEROFIMPORTANCE
 #!.!$!36!,5%02/0/3)4)/.
!SIGNIlCANTPLAYERONTHEINTERNATIONALBIOPHARMACEUTICALSSCENE#ANADASGLOBAL
PRESENCECONTINUESTOGROWSTEADILYTHANKSTOLEADING EDGERESEARCHPROGRAMSAND
STRONGlNANCINGANDVENTURE CAPITALPROGRAMS#ANADAOFFERSANATTRACTIVE
COMBINATIONOFCOST COMPETITIVELOCATIONSANDHIGH QUALITYOPERATINGENVIRONMENTS
TOFULLYINTEGRATEDPHARMACEUTICALlRMSLOOKINGTOPROSPER
#/34!33%33-%.4

#ANADIAN
.ON #ANADIAN
#53

!BETTERRETURNONYOURINVESTMENT
#ANADAOFFERSTHEMOSTCOST COMPETITIVELOCATIONSINCOMPARISON INCLUDINGLARGEBIOPHARMACEUTICALCLUSTERSSUCHAS-ONTRÏAL
TOOTHER.ORTH!MERICANAND'OPTIONSEVALUATEDIN)"- 0,)S AND4ORONTORANKINTHETOPBASEDONAlNANCIALANALYSISOF
BENCHMARKINGSTUDY7INNIPEG3ASKATOONANDTHE#ITYOF1UÏBEC CASHmOWSANDOPERATINGCOSTS7ITHLOWCORPORATETAXRATES
AREAMONGTHETOP#ANADIANLOCATIONSTHATOFFERSIGNIlCANTCOST ANDGENEROUS2$INCENTIVES#ANADIANLOCATIONSHELPINVESTORS
ADVANTAGESOVERCOMPETINGCITIES!LL#ANADIANCITIESBENCHMARKED OPTIMIZETHEIRCOSTSTRUCTURE

15!,)4!4)6%!33%33-%.4/&/0%2!4).'%.6)2/.-%.4

,IVINGENVIRONMENT
2EALESTATE
)NFRASTRUCTURE
COMMUNICATIONS
&LEXIBILITYOFLABOUR
REGULATIONS
0RESENCEOF
INDUSTRYCLUSTER
,OCALPOTENTIALTO
RECRUITSKILLEDSTAFF
'ENERALBUSINESS
ENVIRONMENT

3TRONGCLUSTERSWITHAWEALTHOFEXPERTISE
!PARTFROMOFFERINGCOST COMPETITIVEINVESTMENTLOCATIONS#ANADA #ITYOF1UÏBECALLSCOREHIGHLYINTHISRESPECT#ANADIANLOCATIONS
ALSOOFFERSBIOPHARMACEUTICALlRMSSOMEOFTHEWORLDSBEST ASAWHOLEALSOGAINEXCELLENTSCORESFOR2$ANDFORTHEQUALITY
OPERATINGENVIRONMENTS4ORONTOAND-ONTRÏALBOTHHOMETOMANY OFINFRASTRUCTUREINCLUDINGEASYHIGHWAYACCESSLOWCONGESTION
OFTHETOPBIOPHARMACEUTICALlRMSRANKAMONGLEADING.ORTH ANDRELIABILITYOFTHELOCALPOWERSUPPLYALLKEYINVESTMENTDRIVERS
!MERICANOPTIONS/THER#ANADIANLOCATIONSNOTABLYTHE#ITYOF INTHISINDUSTRYSECTOR4HENEW%5 #ANADAAVIATIONAGREEMENTWILL
1UÏBECAND6ANCOUVERALSOOFFERSTRONGQUALITATIVEENVIRONMENTS SUPPORT#ANADASGROWINGTRANSATLANTICTRADEFACILITATINGTHEEFlCIENT
4HEABILITYTOHIREEMPLOYEESSKILLEDINTHEPHARMACEUTICALINDUSTRY mOWOFPEOPLEANDVALUABLEGOODS
ISANIMPORTANTFACTORINTHISASSESSMENT4ORONTO-ONTRÏALANDTHE

5NLESSOTHERWISENOTEDGRAPHSREPRESENT)"- 0,)ASSESSMENTSCORES 

#!.!$!36!,5%02/0/3)4)/.
%STIMATEDANNUALLABOURCOSTSOFABIOTECHNOLOGY2$ &AVOURABLELABOURCOSTS
OPERATIONHIGHEST RANKINGCITIES

!CALCULATIONOFTHEESTIMATEDANNUALLABOURCOSTSFORATYPICAL
2$FACILITYFOCUSEDONDRUGDISCOVERYANDCLINICALTRIALSSHOWS
THEPOTENTIALFORSIGNIlCANTCOSTSAVINGSOF#ANADIANLOCATIONS
#ANADIAN
.ON #ANADIAN
!LL#ANADIANCITIESEXAMINEDIN)"- 0,)SSTUDYRANKINTHE
#53 TOPANDHAVELOWERCOSTSTHANPROMINENT53COMPETITORS
SUCHAS0HILADELPHIA"OSTONAND*ERSEY#ITY

!NIMPORTANTCOMPONENTOF#ANADASLABOURCOSTADVANTAGE
RELATIVETOTHE5NITED3TATESSTEMSFROMTHELOWERCOSTSOF
PROVIDINGEMPLOYEEBENElTS#ANADASNATIONALHEALTHCARE
SYSTEMIMPLIESTHATMOSTMEDICALINSURANCECOSTSAREPUBLICLY
FUNDEDRATHERTHANPAIDBYTHEEMPLOYERWHICHCANRESULTIN
SIGNIlCANTSAVINGSFOREMPLOYERS

4HRIVINGBIOPHARMACEUTICALCLUSTERS 0RESENCEOFPHARMACEUTICALINDUSTRYBASE
HIGHEST RANKINGCITIES

#LUSTERSOFPHARMACEUTICALCOMPANIESALLOWCLOSELINKAGES
WITHBUYERSSUPPLIERSANDOTHERINSTITUTIONSTOOFFERADVANTAGES
THATLEADNOTONLYTOGREATEREFlCIENCYBUTALSOTOACCELERATED
PRODUCTIMPROVEMENTANDINNOVATION

#ANADAHASTHESECONDHIGHESTNUMBEROFBIOTECHNOLOGY
COMPANIESINTHEWORLDANDISHOMETOSOMEOFTHELARGEST
ESTABLISHEDCLUSTERSINTHEPHARMACEUTICALINDUSTRY/FlCIAL
COUNTSOFESTABLISHMENTSCLASSIlEDASPHARMACEUTICAL #ANADIAN
MANUFACTURINGSHOW4ORONTOAND-ONTRÏALCOMPARING .ON #ANADIAN

WELLTO*ERSEY#ITY.EW*ERSEYONEOFTHEMOSTPROMINENT

PHARMACEUTICALINDUSTRYBASESIN.ORTH!MERICA

,OCALPOTENTIALTORECRUITSKILLEDSTAFF !DEEPTALENTPOOL
HIGHEST RANKINGCITIES

4HEPRESENCEOFEXPERIENCEDCLINICIANSANDRESEARCHERS
CONTRIBUTESTOTHESUCCESSOF2$ACTIVITIES0ROXIMITYTO
UNIVERSITIESANDASTUDENTPOPULATIONAREIMPORTANTINPROVIDING
ASOURCEOFEDUCATEDLABOURASWELLASINDIVIDUALSTOSERVE
ASTESTPOPULATIONSFORHEALTHRESEARCHANDSTUDIES2ANKED
lRSTINTHEWORLDFORHIGHEREDUCATION#ANADAISHOMETOAN
EXCEPTIONALLYWELL EDUCATEDMOTIVATEDANDDIVERSEWORKFORCE

4ORONTO-ONTRÏALTHE#ITYOF1UÏBECAND6ANCOUVERALL

#ANADIAN
HOSTLARGEPOPULATIONSOFEXPERIENCEDEMPLOYEESWORKINGIN
.ON #ANADIAN PHARMACEUTICALANDBIOMEDICAL RELATEDCOMPANIESASWELLAS
LARGESTUDENTPOPULATIONSENSURINGASTEADYmOWOFNEWTALENT

5NLESSOTHERWISENOTEDGRAPHSREPRESENT)"- 0,)ASSESSMENTSCORES

)"- 0,)CALCULATIONSBASEDON7ATSON7YATT%CONOMIC2ESEARCH)NSTITUTE%2) %STABLISHMENTSBELONGINGTO.!)#3

 )-$7ORLD#OMPETITIVENESS9EARBOOK
 #!.!$!36!,5%02/0/3)4)/.
'ENEROUS2$INCENTIVES 4HERATEOFTAXSUBSIDIESFOR53OF2$
LARGElRMSAND3-%S'COUNTRIES

#ANADAUNDERSTANDSTHAT2$ANDINNOVATIONARECRITICALTO
THEGROWTHOFBIOPHARMACEUTICALlRMSTHEREFOREBILLIONSOF
DOLLARSAREINVESTEDIN2$EACHYEARTOENSURETHATINVESTORS
HAVEACCESSTOTHEBESTTALENTANDINFRASTRUCTUREINTHEWORLD
#ANADAPROVIDESASYSTEMOFFEDERALANDPROVINCIALTAXCREDITS
ANDACCELERATEDTAXDEDUCTIONSFORAWIDEVARIETYOF2$
EXPENDITURESTOALLOWGLOBALlRMSTOSIGNIlCANTLYREDUCECOSTS
#ANADIAN
.ON #ANADIAN
#ANADAS3CIENTIlC2ESEARCHAND%XPERIMENTAL$EVELOPMENT
32%$ PROGRAMISANOPEN ENDEDTAXINCENTIVEINITIATIVE
THATCOVERSPERCENTOFVARIOUS2$ RELATEDCOSTSSUCH
ASSALARIESOVERHEADCAPITALEQUIPMENTANDMATERIALS4HE
32%$INCENTIVEPERMITSlRMSTOREDUCE2$COSTSTHROUGH
DIRECTINVESTMENTORSUBCONTRACTINGIN#ANADA

3TUDENTPOPULATIONHIGHEST RANKINGCITIES

4HEPEOPLEADVANTAGE
#ANADABELIEVESININVESTINGINPEOPLEANDWELCOMINGTALENT
FROMAROUNDTHEWORLD4HISHELPSEXPLAINWHY#ANADAHASTHE
WORLDSHIGHESTPERCENTAGEOFCOLLEGEANDUNIVERSITYGRADUATES
ANDAWELL EDUCATEDTALENTEDANDDIVERSEWORKFORCEMOTIVATED
TOHELPBUSINESSESSUCCEED

)"- 0,)SBENCHMARKINGSTUDYRATESlVE#ANADIANCITIES
ATTHETOPOFTHERANKINGSFORTHENUMBEROFLIFESCIENCE
#ANADIAN RELATEDGRADUATES4ORONTO-ONTRÏAL6ANCOUVER/TTAWA
.ON #ANADIAN
AND%DMONTONALLHOSTSIZEABLEUNIVERSITIESWITHFACULTIESIN
BIOLOGICALBIOMEDICALANDGENERALLIFESCIENCESRESULTINGINA
LARGEANDCONSTANTmOWOFNEWTALENTFORTHEINDUSTRY

"ESTPLACETODOBUSINESSINTHE' 'ENERALBUSINESSENVIRONMENTHIGHEST RANKINGCITIES

#ANADAHASASOLIDANDDYNAMICECONOMYLOWCORPORATETAX
RATESANDGENEROUS2$INCENTIVES4HISCOUPLEDWITHTHE
SUPPORTFROMLOCALGOVERNMENTSANDDEVELOPMENTAGENCIES
PRIVACYREGULATIONSINFORMATIONSECURITYANDINTELLECTUAL
PROPERTYRIGHTSHASHELPEDTOMAKE#ANADAANADVANTAGEOUS
BUSINESSENVIRONMENTFORCOMPANIESTOINVESTANDmOURISH

!STHENUMBERONECOUNTRYAMONGTHE'FOR'$0GROWTH
OVERTHELASTDECADEANDWITHTHEWORLDSSOUNDESTBANKING #ANADIAN
SYSTEM#ANADAPROVIDESASAFEANDSTRONGBUSINESS .ON #ANADIAN
ENVIRONMENTTHATOFFERSTREMENDOUSGROWTHPOTENTIALANDPEACE
OFMINDFORYOURINVESTMENT

5NLESSOTHERWISENOTEDGRAPHSREPRESENT)"- 0,)ASSESSMENTSCORES

/%#$3CIENCE4ECHNOLOGYAND)NDUSTRY3COREBOARD

3OURCESINCLUDE.ATIONAL#ENTERFOR%DUCATION
3TATISTICSAND)NTEGRATED0OSTSECONDARY%DUCATION$ATA7ORLD%CONOMIC&ORUM'LOBAL#OMPETITIVENESS2EPORT /CTOBER 
 )NVESTIN#ANADA
ATYOURSERVICE
7EOFFERTHEFOLLOWINGVALUABLESERVICESTOOURCLIENTS
q STRATEGICMARKETINTELLIGENCEONYOURSPECIFICSECTOR
q DIRECTCONTACTWITHKEYDECISION MAKERSINTHEGOVERNMENT
q REFERRALSTOCONTACTSINFIRMSANDINDUSTRYASSOCIATIONSASWELLASEXPERTS
q INFORMATIONANDADVICEONSETTINGUPABUSINESSIN#ANADA
q HELPINIDENTIFYINGASUITABLEPLACEINWHICHTOINVEST
q ASSISTANCEINDEVELOPINGABUSINESSCASEFORYOURNEXTINVESTMENTDECISION

/URGLOBALNETWORKWILLSHOWYOUWHY#ANADAISYOURSTRATEGICCHOICEFORGROWTH

4OREACHANINVESTMENTOFFICERINYOURMARKETPLEASEVISIT

WWWINVESTINCANADACOMGLOBALNETWORK

)NVESTIN#ANADA"UREAU
&OREIGN!FFAIRSAND)NTERNATIONAL4RADE#ANADA
3USSEX$RIVE
/TTAWA/.#ANADA+.*

%MAILINVESTINCANADA INTERNATIONALGCCA
7EBSITEWWWINVESTINCANADACOM

#ATALOGUE.UMBER&2  % 0$&

)3"..UMBER    

4HISPUBLICATIONWASPREPAREDBY)NVESTIN#ANADAINCOOPERATIONWITH)"- 0,)4HEDOCUMENTCOVERSAWIDERANGEOFISSUESANDISNOTINTENDEDTOBEA
DETAILEDNORANEXHAUSTIVEREFERENCE!CCORDINGLYBEFORERELYINGONTHEMATERIALHEREINREADERSSHOULDINDEPENDENTLYVERIFYITSACCURACYCURRENCYAND
RELEVANCEFORTHEIRPURPOSESANDSHOULDSEEKAPPROPRIATEPROFESSIONALADVICE!NYREFERENCETOCOMPANIESORINVESTMENTSISFORILLUSTRATIVEPURPOSESONLY
ANDDOESNOTCONSTITUTEANENDORSEMENTOFTHOSECOMPANIESORINVESTMENTS$ETAILSOFSOURCESFORALLQUOTEDFACTSANDFIGURESAREAVAILABLEUPONREQUEST
4HE'OVERNMENTOF#ANADADOESNOTACCEPTANYLIABILITYINRELATIONTOTHECONTENTSOFTHISWORK4HISPUBLICATIONISPRINTEDONRECYCLEDPAPERANDISAVAILABLE
INMULTIPLELANGUAGESINCLUDING&RENCH¥(ER-AJESTYTHE1UEENIN2IGHTOF#ANADAASREPRESENTEDBYTHE-INISTEROF)NTERNATIONAL4RADE